众生药业
(002317)
| 流通市值：96.34亿 | | | 总市值：107.72亿 |
| 流通股本：7.62亿 | | | 总股本：8.52亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 990,260,147.47 | 1,399,449,534.39 | 766,131,361.53 | 971,641,672.77 |
| 结算备付金 | 0 | 0 | 0 | 0 |
| 拆出资金 | 0 | 0 | 0 | 0 |
| 衍生金融资产 | 0 | 0 | 0 | 0 |
| 应收票据及应收账款 | 1,245,611,393.93 | 999,601,559.33 | 1,030,733,355.47 | 1,105,924,854.42 |
| 其中：应收票据 | 674,582,002.93 | 466,394,068.02 | 449,432,196.41 | 542,359,529.92 |
| 应收账款 | 571,029,391 | 533,207,491.31 | 581,301,159.06 | 563,565,324.5 |
| 应收款项融资 | 230,000 | 0 | 740,000 | 0 |
| 预付款项 | 66,170,806.32 | 84,200,904.09 | 84,724,481.2 | 89,186,182.38 |
| 应收保费 | 0 | 0 | 0 | 0 |
| 应收分保账款 | 0 | 0 | 0 | 0 |
| 应收分保合同准备金 | 0 | 0 | 0 | 0 |
| 其他应收款合计 | 12,044,017.92 | 17,260,459.7 | 18,786,244.49 | 17,108,193.73 |
| 其中:应收利息 | 0 | 0 | 0 | 0 |
| 应收股利 | 0 | 0 | 0 | 0 |
| 买入返售金融资产 | 0 | 0 | 0 | 0 |
| 存货 | 377,638,590.28 | 441,477,244.29 | 483,679,034.01 | 504,835,619.25 |
| 合同资产 | 0 | 0 | 0 | 0 |
| 一年内到期的非流动资产 | 164,973,722.34 | 163,693,996.31 | 162,385,831.93 | 129,198,023.71 |
| 其他流动资产 | 79,959,019.06 | 51,129,904.63 | 102,314,390.88 | 101,277,325.16 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 3,142,454,645.15 | 3,462,803,674.1 | 3,260,603,051.47 | 3,208,680,366.28 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | 0 | 0 | 0 | 0 |
| 债权投资 | 0 | 0 | 0 | 0 |
| 其他债权投资 | 0 | 0 | 0 | 0 |
| 长期应收款 | 0 | 0 | 0 | 0 |
| 长期股权投资 | 1,746,711.22 | 2,444,998.92 | 3,653,444.06 | 4,195,591.32 |
| 其他权益工具投资 | 112,301,586.71 | 115,630,991.16 | 121,848,333.67 | 122,138,426.84 |
| 其他非流动金融资产 | 34,765,000 | 34,765,000 | 34,765,000 | 34,765,000 |
| 投资性房地产 | 13,904,742.23 | 14,221,588.83 | 14,544,906.07 | 3,267,408.44 |
| 固定资产 | 647,189,288.34 | 658,108,744.16 | 667,009,547.04 | 688,895,983.48 |
| 在建工程 | 25,885,503.43 | 27,584,462.61 | 11,059,418.56 | 5,262,782.41 |
| 生产性生物资产 | 0 | 0 | 0 | 0 |
| 油气资产 | 0 | 0 | 0 | 0 |
| 使用权资产 | 1,063,068.24 | 1,669,663.17 | 1,530,207.27 | 2,107,655.52 |
| 无形资产 | 319,366,876.53 | 327,110,969.26 | 422,638,526.24 | 434,915,243.96 |
| 开发支出 | 494,967,899.96 | 480,297,636.73 | 632,977,582.34 | 616,941,056.5 |
| 商誉 | 6,949,110.48 | 6,949,110.48 | 208,626,197.09 | 208,626,197.09 |
| 长期待摊费用 | 817,732.52 | 1,351,643.92 | 1,986,442.13 | 2,277,899.67 |
| 递延所得税资产 | 23,498,533.19 | 29,688,434.02 | 49,250,395.65 | 45,984,040.6 |
| 其他非流动资产 | 407,864,627.09 | 390,866,315.91 | 389,553,395.62 | 412,352,262.31 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,090,320,679.94 | 2,090,689,559.17 | 2,559,443,395.74 | 2,581,729,548.14 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,232,775,325.09 | 5,553,493,233.27 | 5,820,046,447.21 | 5,790,409,914.42 |
| 流动负债: | | | | |
| 短期借款 | 353,259,659.15 | 303,461,626.85 | 0 | 0 |
| 向中央银行借款 | 0 | 0 | 0 | 0 |
| 吸收存款及同业存放 | 0 | 0 | 0 | 0 |
| 拆入资金 | 0 | 0 | 0 | 0 |
| 交易性金融负债 | 0 | 0 | 0 | 0 |
| 衍生金融负债 | 0 | 0 | 0 | 0 |
| 应付票据及应付账款 | 103,103,031.35 | 93,099,673.7 | 110,543,621.17 | 138,966,930.91 |
| 其中：应付票据 | 18,000,000 | 21,519,560 | 16,349,273.75 | 33,579,823 |
| 应付账款 | 85,103,031.35 | 71,580,113.7 | 94,194,347.42 | 105,387,107.91 |
| 预收款项 | 239,546.2 | 52,643 | 107,364.56 | 8,850.2 |
| 合同负债 | 20,127,950 | 20,080,617.64 | 26,269,307.93 | 21,997,855.45 |
| 卖出回购金融资产款 | 0 | 0 | 0 | 0 |
| 应付手续费及佣金 | 0 | 0 | 0 | 0 |
| 应付职工薪酬 | 16,748,958.11 | 48,905,078.02 | 19,567,148.59 | 18,239,206.92 |
| 应交税费 | 40,888,566.27 | 35,216,203.7 | 65,962,176.64 | 63,057,954 |
| 其他应付款合计 | 162,958,696.81 | 162,741,665.58 | 127,035,020.62 | 178,537,498.87 |
| 其中:应付利息 | 0 | 0 | 0 | 0 |
| 应付股利 | 0 | 0 | 0 | 0 |
| 应付分保账款 | 0 | 0 | 0 | 0 |
| 保险合同准备金 | 0 | 0 | 0 | 0 |
| 代理买卖证券款 | 0 | 0 | 0 | 0 |
| 代理承销证券款 | 0 | 0 | 0 | 0 |
| 一年内到期的非流动负债 | 76,568,613.07 | 522,562,644.04 | 1,613,229.43 | 2,289,150.63 |
| 其他流动负债 | 27,188,084.97 | 17,358,005.86 | 67,234,035.59 | 76,670,556.97 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 801,083,105.93 | 1,203,478,158.39 | 418,331,904.53 | 499,768,003.95 |
| 非流动负债: | | | | |
| 长期借款 | 0 | 0 | 0 | 0 |
| 应付债券 | 0 | 0 | 0 | 0 |
| 优先股 | 0 | 0 | 0 | 0 |
| 永续债 | 0 | 0 | 0 | 0 |
| 租赁负债 | 309,850.31 | 304,588.31 | 306,409.04 | 299,604.47 |
| 长期应付款 | 140,128,436.42 | 138,758,146.06 | 657,828,208.57 | 652,345,399.12 |
| 长期应付职工薪酬 | 0 | 0 | 0 | 0 |
| 预计负债 | 0 | 0 | 0 | 0 |
| 递延收益 | 158,994,310.17 | 161,940,821.31 | 162,243,003.69 | 163,348,113.41 |
| 递延所得税负债 | 38,246,233.26 | 38,897,110.19 | 38,173,024.39 | 31,252,334.61 |
| 其他非流动负债 | 0 | 0 | 0 | 0 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 337,678,830.16 | 339,900,665.87 | 858,550,645.69 | 847,245,451.61 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,138,761,936.09 | 1,543,378,824.26 | 1,276,882,550.22 | 1,347,013,455.56 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 851,556,477 | 851,556,477 | 851,556,477 | 853,350,477 |
| 其他权益工具 | 0 | 0 | 0 | 0 |
| 优先股 | 0 | 0 | 0 | 0 |
| 永续债 | 0 | 0 | 0 | 0 |
| 资本公积 | 1,779,489,433.25 | 1,779,544,967.96 | 1,800,475,893 | 1,814,236,409.96 |
| 减:库存股 | 8,097,480 | 8,097,480 | 8,097,480 | 66,456,772.71 |
| 其他综合收益 | 52,020,388.46 | 54,855,188.11 | 56,914,239.61 | 57,217,033.61 |
| 专项储备 | 0 | 0 | 0 | 0 |
| 盈余公积 | 321,501,033.58 | 321,501,033.58 | 321,501,033.58 | 321,501,033.58 |
| 一般风险准备 | 0 | 0 | 0 | 0 |
| 未分配利润 | 998,024,718.7 | 915,412,879.6 | 1,363,372,423.71 | 1,301,979,777.79 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,994,494,570.99 | 3,914,773,066.25 | 4,385,722,586.9 | 4,281,827,959.23 |
| 少数股东权益 | 99,518,818.01 | 95,341,342.76 | 157,441,310.09 | 161,568,499.63 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 4,094,013,389 | 4,010,114,409.01 | 4,543,163,896.99 | 4,443,396,458.86 |
| 负债和股东权益合计 | 5,232,775,325.09 | 5,553,493,233.27 | 5,820,046,447.21 | 5,790,409,914.42 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-29 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |